

## tixagevimab and cilgavimab solution for injection (Evusheld®)

Astra Zeneca UK Limited

08 May 2024

The Scottish Medicines Consortium (SMC) collaborated with the National Institute for Health and Care Excellence (NICE) and following review by the SMC Executive, SMC advises NHS boards and Area Drug and Therapeutics Committees (ADTCs) on the use of the above product in NHSScotland. The advice is as follows:

**ADVICE:** following SMC collaboration with NICE on *TA971: remdesivir and tixagevimab plus cilgavimab for treating COVID-19*.

**tixagevimab and cilgavimab (Evusheld®)** is not recommended within NHSScotland.

**Indication under review:** treatment of COVID-19 in adults who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

Full details of the assessment and recommendations can be found at [Overview | Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 | Guidance | NICE](#).

### Advice context:

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at following collaboration with NICE. It is provided to inform the considerations of Area Drug and Therapeutics Committees and NHS boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

Chair

Scottish Medicines Consortium